Novel HER2 Conjugate Promising as Salvage for Solid Tumors
A small trial of a new antibody-drug conjugate that targets HER2 produced an objective response rate of 43% in patients with HER2-positive... Read More
For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org
Together, we will defeat stomach cancer.
Together, we will defeat stomach cancer.
MORE INFODONATE